Hot Investor Mandate: Western Europe VC Invests Up to $5M In Early Stage Therapeutics, With Strong Interests in Advanced Therapies in Immuno-Oncology

5 Nov

A Western Europe-based fund is interested in advanced therapeutics. The firm invests both publicly and privately throughout the US, and Europe. For private deals, the firm makes equity deals in early-stage biotech therapeutic companies. The firm typically looks to make 8-10 deals in the private sector through each yearly cycle and typically allocates between $1M – $5M in each deal. The firm typically follows on these investments, preferring not to lead.  The firm typically invests in seed and Series A rounds.

The firm is currently seeking biotech therapeutics that are considered advanced therapeutics. Examples of some therapies that the firm considers as advanced therapies are cell therapies and gene therapies. Currently, the firm is interested in immuno-oncology therapeutics, but is not interested in checkpoint inhibitors. For these therapeutics companies, they prefer that the asset is currently pre-clinical, in Phase I, or ready for phase II. The firm is agnostic in terms of specific indications.

The firm prefers investing in companies located in the European Union, but typically finds that a good amount of their deals are based in the United States. The firm is open to other geographies, but has yet to see a deal that is particularly interesting to them from other areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: